Aurobindo Pharma on Monday said two of its facilities have undergone inspection by US health regulator USFDA, which has issued observations for one unit. Shares of the pharma firm on BSE fell 3.89% to close at Rs 800.80 on Monday.
“The said facilities underwent pre-approval inspection by the United States Food and Drug Administration (USFDA) and with regard to unit VII, there were certain observations,” Aurobindo Pharma said in a filing to BSE. There were no observations on the other unit (unit III) that was inspected.
The FDA has increased the number of inspections of foreign plants supplying to the US over the past year.